ADXN - Pangali Forward P/E addextherapeutics.com
Addex Therapeutics is optimizing costs by utilizing a virtual drug development model and European contractors. The company's consensus forward P/E clearly demonstrates market expectations, where 0.00 serves as the current metric level. However, geopolitical tensions and logistics disruptions are hindering clinical trials. Currently, financial stability relies on partner payments, as the company lacks its own commercial products.
Rincian metrik keuangan lan pasar Addex (ADXN)
- kuotasi lan prakiraan analis:
- statistik kapitalisasi pasar:
- informasi kapitalisasi buku:
- rincian struktur utang lan likuiditas bisnis:
Rasio Total Utang marang Ekuitas Addex Therapeutics|ADXN - Koefisien utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Addex Therapeutics|ADXN - Tanggungan utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Addex Therapeutics Ltd.|ADXN - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Addex Therapeutics|Likuiditas cepet addextherapeutics.com
- statistik bathi lan rasio pasar:
ADXN - Bathi pungkasan|Proyeksi bathi mangsa ngarep Addex Therapeutics|ADXN - Pangali P/E|Rega marang bathi mangsa ngarep Addex Therapeutics, Ltd.|ADXN - Rasio kapitalisasi marang bathi lan wutah|Pangali EV/EBITDA Addex Therapeutics Ltd.|ADXN - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Addex Therapeutics|ADXN - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan addextherapeutics.com|ADXN - Wutah bathi resik saben siji saham kanggo taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Addex Therapeutics
Ringkesan analisis perusahaan:Addex Therapeutics Ltd
Forward P/E assesses asset value through the ratio of current price to projected earnings for the following year, allowing for the determination of the premium paid for future income. Analyzing the projected P/E multiple of Addex Therapeutics (ADXN) at 0.00, an investor identifies risks where a chronic deficit in operating cash flow and a reliance on grants render this calculation purely speculative.
Pesaing langsung
Pangali Forward P/E BIIB|Neurocrine - Rasio rega marang bathi mangsa ngarep|Pangali Forward P/E RGC (Regencell)|AXSM: Rasio rega marang bathi mangsa ngarep|ACADIA Pharmaceuticals - Pangali Forward P/E|Rasio prakiraan rega marang bathi xenon-pharma.com|VKTX (Viking Therapeutics, Inc.) - Prakiraan rega marang bathi|Rasio rega marang bathi mangsa ngarep SUPN|Prakiraan rega marang bathi CPRX|DNLI: Pangali mangsa ngarep rega marang bathi|Prakiraan rega marang bathi HRMY (Harmony Biosciences)|Rasio kapitalisasi marang bathi mangsa ngarep BHVN|Pangali Forward P/E AMLX (Amylyx Pharmaceuticals, Inc.)|Pangali mangsa ngarep rega marang bathi TRVI|Praxis Medicines - Pangali Forward P/E|Rasio prakiraan rega marang bathi Anavex Life Sciences Corp|CeriBell, Inc. (CBLL) - Rega marang bathi mangsa ngarep|Prothena - Pangali mangsa ngarep rega marang bathi|ALEC (Alector Inc.) - Pangali Forward P/E|Pangali Forward P/E Annexon Biosciences|Rega marang bathi mangsa ngarep Omeros Corporation (OMER)|NGNE: Rasio rega marang bathi sing dikarepake|Pangali Forward P/E ACIU (AC Immune)|voyagertherapeutics.com (VYGR) - Rasio prakiraan rega marang bathi|NMRA: Prakiraan rega marang bathi|SCLX - Pangali Forward P/E|TVGN (Tevogen Bio Holdings, Inc.) - Prakiraan rega marang bathi|ACOG: Rasio kapitalisasi marang bathi mangsa ngarep|CGTX (Cognition Therapeutics) - Pangali Forward P/E|inhibikase.com (IKT) - Kapitalisasi marang proyeksi bathi|Pangali Forward P/E SAVA|Prakiraan rega marang bathi assertiotx.com ASRT|Rega marang bathi mangsa ngarep Coya Therapeutics COYA|Kapitalisasi marang proyeksi bathi VistaGen Therapeutics, Inc. (VTGN)|Ovid Rx - Pangali Forward P/E|ABOS - Pangali Forward P/E|CRVO: Pangali Forward P/E|Rasio rega marang bathi mangsa ngarep ATHE|Prakiraan rega marang bathi CLNN|Rasio rega marang bathi mangsa ngarep PEPG (PepGen Corp)|Rega marang bathi mangsa ngarep Jupiter Neurosciences Inc (JUNS)|relmada.com - Rasio rega marang bathi mangsa ngarep|Rega marang bathi mangsa ngarep Annovis Bio ANVS|GRCE: Rasio rega marang bathi mangsa ngarep|Firefly Neuroscience Inc - Pangali Forward P/E|Rasio prakiraan rega marang bathi Klotho Neurosciences Inc|NRSN (neurosense-tx.com) - Prakiraan rega marang bathi|revivapharma.com (RVPH) - Pangali Forward P/E|Rega marang bathi mangsa ngarep MetaVia Inc.|NRXS: Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Helius Medical (HSDT)|PASG - Rasio prakiraan rega marang bathi|Pangali Forward P/E NEUP (Neuphoria Therapeutics)|Pangali Forward P/E minervaneurosciences.com NERV|Athira Pharma - Pangali Forward P/E|ALZN (Alzamend Neuro, Inc.) - Rasio rega marang bathi mangsa ngarep|CYCN: Pangali Forward P/E|Rasio rega marang bathi mangsa ngarep PTIX|KTTA (Pasithea Therapeutics Corp) - Pangali Forward P/E|Rasio prakiraan rega marang bathi Cortigent Medical CRGT|Prakiraan rega marang bathi ATXI (Avenue Therapeutics, Inc.)|Brainstorm Cell Therapeutics Inc. - Rasio rega marang bathi mangsa ngarep|Cara Therapeutics, Inc - Prakiraan rega marang bathi|Pangali mangsa ngarep rega marang bathi CHRO|ELYM: Prakiraan rega marang bathi|Intra-Cellular Therapies - Rasio kapitalisasi marang bathi mangsa ngarep|LBPH: Pangali Forward P/E|Marinus Pharmaceuticals Inc - Pangali mangsa ngarep rega marang bathi|NKGN (NKGen) - Pangali Forward P/E|Rasio prakiraan rega marang bathi NeuroBo Pharma NRBO|Rega marang bathi mangsa ngarep Sage Therapeutics, Inc. (SAGE)|SNPX (synaptogen.com) - Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E TRVN (Trevena)|Pangali Forward P/E Vigil Neuroscience Inc. VIGL|WENA - Rega marang bathi mangsa ngarep|Rasio rega marang bathi sing dikarepake CERE
